Nectar Lifesciences Limited has informed the Exchange with copy of minutes of Extraordinary General Meeting held on August 04, 2025
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences held an EGM on August 4, 2025, where three resolutions were approved by shareholders. The most significant was the slump sale of the company's entire business — manufacturing, distribution, marketing and sale of active pharmaceutical ingredients (APIs) and formulations — to Ceph Lifesciences Private Limited for a total consideration of Rs 1,270 crore. The company stated the sale proceeds will be used to repay existing debt, invest in new projects, reward shareholders through special dividends and/or a buyback, and meet general corporate purposes. Shareholders also approved the appointment of Dr. Surulichamy Senthilkumar as a Wholetime Director (R&D) for three years at a monthly salary of Rs 6 lakh, along with his appointment as a Director liable to retire by rotation. All three resolutions passed with over 98% votes in favour, although around 9.8% of public shareholders voted against the slump sale resolution in e-voting.
This is a transformational event for Nectar Lifesciences — the company is divesting its entire operating business for Rs 1,270 crore, which could mean a potential special dividend or buyback for shareholders. However, investors should track how the proceeds are ultimately deployed, as the future business profile of the listed entity changes materially post the slump sale.